New drugs 99, Part III.
Hussar
D A
DA
Philadelphia College of Pharmacy, University of the Sciences, Pa., USA.
D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D048588:Benzoxazines; D003521:Cyclopropanes; D015224:Dideoxynucleosides / Q000627:therapeutic use; D016903:Drug Monitoring / Q000379:methods / Q000451:nursing; D004358:Drug Therapy / Q000451:nursing*; D064420:Drug-Related Side Effects and Adverse Reactions; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D007917:Leprostatic Agents / Q000627:therapeutic use; D010001:Osteitis Deformans / Q000188:drug therapy; D010078:Oxazines / Q000627:therapeutic use; D012293:Rifampin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000068296:Risedronic Acid; D013792:Thalidomide / Q000627:therapeutic use; D013873:Thionucleotides / Q000627:therapeutic use; D000068878:Trastuzumab; D000099227:Abacavir
D000480:Alkynes; D019380:Anti-HIV Agents; D000904:Antibiotics, Antitubercular; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D015224:Dideoxynucleosides; D012968:Etidronic Acid; D000069285:Infliximab; D007917:Leprostatic Agents; D010078:Oxazines; D012293:Rifampin; D000068296:Risedronic Acid; D013792:Thalidomide; D013873:Thionucleotides; D000068878:Trastuzumab; D000099227:Abacavir; C098320:efavirenz; C091346:fomivirsen; C018421:rifapentine